Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeutics 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NY 27560 USA

www.tgtherapeutics.com Employees: 264 P: 877-575-8489

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 4,836,511
Enterprise Value, $K 4,843,701
Shares Outstanding, K 155,665
Annual Sales, $ 233,660 K
Annual Net Income, $ 12,670 K
Last Quarter Sales, $ 83,880 K
Last Quarter Net Income, $ 3,880 K
EBIT, $ -510 K
EBITDA, $ 50 K
60-Month Beta 2.25
% of Insider Shareholders 10.50%
% of Institutional Shareholders 58.58%
Float, K 139,320
% Float 89.50%
Short Volume Ratio 0.52

Growth:

1-Year Return 70.81%
3-Year Return 60.24%
5-Year Return 185.57%
5-Year Revenue Growth 155,673.33%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.02 on 11/04/24
Next Earnings Date N/A
Earnings Per Share ttm -0.10
EPS Growth vs. Prev Qtr -50.00%
EPS Growth vs. Prev Year -97.26%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 196.57
Price/Earnings to Growth N/A
Return-on-Equity % -8.32%
Return-on-Assets % -3.40%
Profit Margin % 5.42%
Debt/Equity 1.27
Price/Sales 22.36
Price/Cash Flow 393.48
Price/Book 27.72
Book Value/Share 1.24
Interest Coverage 2.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar